In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer. In 2018, it is approved in the United States for the treatment of breast, pancreatic, ovarian, Kaposis sarcoma and non-small-cell lung cancers. Similar compounds
Albumin-bound paclitaxel (trade name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is bound to albumin nanoparticles. Much of the clinical toxicity of paclitaxel is associated with the solvent Cremophor EL in which it is dissolved for delivery.Abraxis BioScience developed Abraxane, in which paclitaxel is bonded to albumin as an alternative delivery agent to the often toxic solvent delivery method. This was approved by the FDA in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. It has since been approved for locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas as well.Synthetic approaches to paclitaxel production led to the development of docetaxel. Docetaxel has a similar set of clinical uses to paclitaxel, and it is marketed under the brand name Taxotere. Taxanes, including paclitaxel, 10-deacetylbaccatin III, baccatin III, paclitaxel C, and 7-epipaclitaxel, have been found in the leaves and shells of hazel. The finding of these compounds in shells, which are considered discarded material and are mass-produced by many food industries, is of interest for the future availability of paclitaxel.
{{cite journal}}:  CS1 maint: multiple names: authors list (link)
Seeman M.V. (2016). "Erotomania and recommendations for treatment". Psychiatric Quarterly. 87 (2): 355–364. doi:10.1007/s11126-015-9392-0. PMID 26442945. S2CID 13059293. Segal J.H. (1989). "Erotomania revisited: From Kraepelin to DSM-III-R". The American Journal of Psychiatry. 146 (10): 1261–6. doi:10.1176/ajp.146.10.1261. PMID 2675641.